Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma

Nozomi Niitsu, Masataka Okamoto, Hirokazu Nakamine, Tadashi Yoshino, Jun Ichi Tamaru, Shigeo Nakamura, Masaaki Higashihara, Masami Hirano

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Therapeutic approaches for non-Hodgkin's lymphoma (NHL) are currently based on the International Prognostic Index (IPI). Research on biological prognostic factors has been actively pursued in recent years, with serum vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) being identified as prognostic factors for NHL. Here, we determined that serum VEGF and IL-6 levels are independent prognostic factors for aggressive lymphoma. Compared with normal controls, serum VEGF and IL-6 levels were significantly higher in patients with aggressive lymphoma or adult T-cell leukemia/lymphoma. Furthermore, overall and disease-free survival rates for patients with high levels of VEGF or IL-6 were significantly poorer than for patients with low levels. In addition, the prognosis for patients with high levels of both serum VEGF and IL-6 was significantly poorer than that for patients with high levels of either VEGF or IL-6 or with low levels of both VEGF and IL-6. Multivariate analyses of a variety of prognostic factors, including the five IPI factors, revealed that serum VEGF and IL-6 were both independent prognostic factors for overall survival of aggressive lymphoma. Therefore, a combination of VEGF and IL-6 represents a useful prognostic factor for aggressive lymphoma.

Original languageEnglish
Pages (from-to)91-100
Number of pages10
JournalEuropean Journal of Haematology
Volume68
Issue number2
DOIs
Publication statusPublished - 2002

Fingerprint

Non-Hodgkin's Lymphoma
Vascular Endothelial Growth Factor A
Interleukin-6
Serum
Lymphoma
Adult T Cell Leukemia Lymphoma
Biological Factors
Disease-Free Survival
Multivariate Analysis
Survival Rate
Survival
Research

Keywords

  • Interleukin-6 (IL-6)
  • Non-Hodgkin's lymphoma
  • Prognostic factor
  • Serum vascular endothelial growth factor (s-VEGF)

ASJC Scopus subject areas

  • Hematology

Cite this

Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. / Niitsu, Nozomi; Okamoto, Masataka; Nakamine, Hirokazu; Yoshino, Tadashi; Tamaru, Jun Ichi; Nakamura, Shigeo; Higashihara, Masaaki; Hirano, Masami.

In: European Journal of Haematology, Vol. 68, No. 2, 2002, p. 91-100.

Research output: Contribution to journalArticle

Niitsu, Nozomi ; Okamoto, Masataka ; Nakamine, Hirokazu ; Yoshino, Tadashi ; Tamaru, Jun Ichi ; Nakamura, Shigeo ; Higashihara, Masaaki ; Hirano, Masami. / Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. In: European Journal of Haematology. 2002 ; Vol. 68, No. 2. pp. 91-100.
@article{b21b9f8b1ad54d5294526df3b3ebfdcc,
title = "Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma",
abstract = "Therapeutic approaches for non-Hodgkin's lymphoma (NHL) are currently based on the International Prognostic Index (IPI). Research on biological prognostic factors has been actively pursued in recent years, with serum vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) being identified as prognostic factors for NHL. Here, we determined that serum VEGF and IL-6 levels are independent prognostic factors for aggressive lymphoma. Compared with normal controls, serum VEGF and IL-6 levels were significantly higher in patients with aggressive lymphoma or adult T-cell leukemia/lymphoma. Furthermore, overall and disease-free survival rates for patients with high levels of VEGF or IL-6 were significantly poorer than for patients with low levels. In addition, the prognosis for patients with high levels of both serum VEGF and IL-6 was significantly poorer than that for patients with high levels of either VEGF or IL-6 or with low levels of both VEGF and IL-6. Multivariate analyses of a variety of prognostic factors, including the five IPI factors, revealed that serum VEGF and IL-6 were both independent prognostic factors for overall survival of aggressive lymphoma. Therefore, a combination of VEGF and IL-6 represents a useful prognostic factor for aggressive lymphoma.",
keywords = "Interleukin-6 (IL-6), Non-Hodgkin's lymphoma, Prognostic factor, Serum vascular endothelial growth factor (s-VEGF)",
author = "Nozomi Niitsu and Masataka Okamoto and Hirokazu Nakamine and Tadashi Yoshino and Tamaru, {Jun Ichi} and Shigeo Nakamura and Masaaki Higashihara and Masami Hirano",
year = "2002",
doi = "10.1034/j.1600-0609.2002.01609.x",
language = "English",
volume = "68",
pages = "91--100",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma

AU - Niitsu, Nozomi

AU - Okamoto, Masataka

AU - Nakamine, Hirokazu

AU - Yoshino, Tadashi

AU - Tamaru, Jun Ichi

AU - Nakamura, Shigeo

AU - Higashihara, Masaaki

AU - Hirano, Masami

PY - 2002

Y1 - 2002

N2 - Therapeutic approaches for non-Hodgkin's lymphoma (NHL) are currently based on the International Prognostic Index (IPI). Research on biological prognostic factors has been actively pursued in recent years, with serum vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) being identified as prognostic factors for NHL. Here, we determined that serum VEGF and IL-6 levels are independent prognostic factors for aggressive lymphoma. Compared with normal controls, serum VEGF and IL-6 levels were significantly higher in patients with aggressive lymphoma or adult T-cell leukemia/lymphoma. Furthermore, overall and disease-free survival rates for patients with high levels of VEGF or IL-6 were significantly poorer than for patients with low levels. In addition, the prognosis for patients with high levels of both serum VEGF and IL-6 was significantly poorer than that for patients with high levels of either VEGF or IL-6 or with low levels of both VEGF and IL-6. Multivariate analyses of a variety of prognostic factors, including the five IPI factors, revealed that serum VEGF and IL-6 were both independent prognostic factors for overall survival of aggressive lymphoma. Therefore, a combination of VEGF and IL-6 represents a useful prognostic factor for aggressive lymphoma.

AB - Therapeutic approaches for non-Hodgkin's lymphoma (NHL) are currently based on the International Prognostic Index (IPI). Research on biological prognostic factors has been actively pursued in recent years, with serum vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) being identified as prognostic factors for NHL. Here, we determined that serum VEGF and IL-6 levels are independent prognostic factors for aggressive lymphoma. Compared with normal controls, serum VEGF and IL-6 levels were significantly higher in patients with aggressive lymphoma or adult T-cell leukemia/lymphoma. Furthermore, overall and disease-free survival rates for patients with high levels of VEGF or IL-6 were significantly poorer than for patients with low levels. In addition, the prognosis for patients with high levels of both serum VEGF and IL-6 was significantly poorer than that for patients with high levels of either VEGF or IL-6 or with low levels of both VEGF and IL-6. Multivariate analyses of a variety of prognostic factors, including the five IPI factors, revealed that serum VEGF and IL-6 were both independent prognostic factors for overall survival of aggressive lymphoma. Therefore, a combination of VEGF and IL-6 represents a useful prognostic factor for aggressive lymphoma.

KW - Interleukin-6 (IL-6)

KW - Non-Hodgkin's lymphoma

KW - Prognostic factor

KW - Serum vascular endothelial growth factor (s-VEGF)

UR - http://www.scopus.com/inward/record.url?scp=0036251241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036251241&partnerID=8YFLogxK

U2 - 10.1034/j.1600-0609.2002.01609.x

DO - 10.1034/j.1600-0609.2002.01609.x

M3 - Article

C2 - 12038454

AN - SCOPUS:0036251241

VL - 68

SP - 91

EP - 100

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 2

ER -